- Home
- SGHT vs HRTX Comparison
SGHT vs HRTX Comparison
Compare SGHT & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- HRTX
- Stock Information
- Founded
- SGHT 2011
- HRTX 1983
- Country
- SGHT United States
- HRTX United States
- Employees
- SGHT N/A
- HRTX N/A
- Industry
- SGHT Medical Specialities
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- HRTX Health Care
- Exchange
- SGHT Nasdaq
- HRTX Nasdaq
- Market Cap
- SGHT 304.4M
- HRTX 317.0M
- IPO Year
- SGHT 2021
- HRTX 1987
- Fundamental
- Price
- SGHT $5.62
- HRTX $1.78
- Analyst Decision
- SGHT Buy
- HRTX Strong Buy
- Analyst Count
- SGHT 6
- HRTX 3
- Target Price
- SGHT $7.20
- HRTX $6.00
- AVG Volume (30 Days)
- SGHT 144.8K
- HRTX 1.5M
- Earning Date
- SGHT 11-07-2024
- HRTX 11-12-2024
- Dividend Yield
- SGHT N/A
- HRTX N/A
- EPS Growth
- SGHT N/A
- HRTX N/A
- EPS
- SGHT N/A
- HRTX N/A
- Revenue
- SGHT $79,395,000.00
- HRTX $136,361,000.00
- Revenue This Year
- SGHT $3.39
- HRTX $18.46
- Revenue Next Year
- SGHT $11.43
- HRTX $21.59
- P/E Ratio
- SGHT N/A
- HRTX N/A
- Revenue Growth
- SGHT N/A
- HRTX 15.60
- 52 Week Low
- SGHT $1.04
- HRTX $0.50
- 52 Week High
- SGHT $8.45
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- SGHT 42.60
- HRTX 40.87
- Support Level
- SGHT $5.74
- HRTX $1.43
- Resistance Level
- SGHT $6.08
- HRTX $1.93
- Average True Range (ATR)
- SGHT 0.31
- HRTX 0.13
- MACD
- SGHT -0.00
- HRTX -0.01
- Stochastic Oscillator
- SGHT 32.58
- HRTX 48.61
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.